Page 7 - HIV/AIDS Guidelines

Table 9b. Trough Concentrations of Antiretroviral Drugs for
Treatment-Experienced Patients with Virologic Failure.....................................................H-18
Discontinuation or Interruption of Antiretroviral Therapy .......................................................H-19

Considerations for Antiretroviral Use in Special Patient Populations ........................................I-1
Acute HIV Infection .....................................................................................................................I-1

Table 10. Identifying, Diagnosing, and Managing Acute HIV-1 Infection.............................I-4
HIV-Infected Adolescents and Young Adults ...............................................................................I-6
HIV and Illicit Drug Users..........................................................................................................I-11
Table 11. Drug Interactions between Antiretroviral Agents and Drugs
Used to Treat Opioid Addiction............................................................................................I-14
HIV-Infected Women..................................................................................................................I-17
HIV-2 Infection...........................................................................................................................I-24
HIV and the Older Patient ..........................................................................................................I-27

Considerations for Antiretroviral Use in Patients with Coinfections...........................................J-1
HIV/Hepatitis B Virus (HBV) Coinfection..................................................................................J-1

HIV/Hepatitis C Virus (HCV) Coinfection..................................................................................J-5
Mycobacterium tuberculosis Disease with HIV Coinfection.....................................................J-12
Limitations to Treatment Safety and Efficacy ................................................................................K-1
Adherence to Antiretroviral Therapy ..........................................................................................K-1

Table 12. Strategies to Improve Adherence to Antiretroviral Therapy .................................K-4
Adverse Effects of Antiretroviral Agents....................................................................................K-7
Table 13. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects........K-8
Drug Interactions.......................................................................................................................K-14

Table 14. Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonist .........K-17
Table 15a. Drug Interactions between PIs and Other Drugs .............................................K-19
Table 15b. Drug Interactions between NNRTIs and Other Drugs......................................K-30
Table 15c. Drug Interactions between NRTIs and Other Drugs (Including ARV Agents)..K-36
Table 15d. Drug Interactions between CCR5 Antagonist and Other Drugs.......................K-38
Table 15e. Drug Interactions between Integrase Inhibitor and Other Drugs.....................K-39

Table 16a. Interactions among PIs .....................................................................................K-40
Table 16b. Interactions between NNRTIs, MVC, RAL, and PIs..........................................K-41

Preventing Secondary Transmission of HIV...................................................................................L-1
Conclusion ...........................................................................................................................................M-1

Appendix A: Key to Acronyms...........................................................................................................N-1

Appendix B: Drug Characteristics Tables.......................................................................................O-1
Appendix B, Table 1. Characteristics of NRTIs..........................................................................O-1
Appendix B, Table 2. Characteristics of NNRTIs.......................................................................O-4
Appendix B, Table 3. Characteristics of PIs ...............................................................................O-6

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents v

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.